TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02256800

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: UGTIA1 genotyping (7,7)
Description: The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (120 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 180 mg/m2.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: UGT1A1 non-genotyping
Description: The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab (Avastin)
Description: bevacizumab as target therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab (Avastin)
Description: bevacizumab as target therapy
Study: NCT02256800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab (Avastin)
Description: bevacizumab as target therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab (Avastin)
Description: bevacizumab as target therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: irinotecan as escalating dose according to UGT1A1 genotyping

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: irinotecan as escalating dose according to UGT1A1 genotyping

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: irinotecan as escalating dose according to UGT1A1 genotyping

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: irinotecan as escalating dose according to UGT1A1 genotyping

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: combined with 5-FU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: combined with 5-FU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: combined with 5-FU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: combined with 5-FU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: combined with irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: combined with irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: combined with irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: combined with irinotecan
Study: NCT00805376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNX-2401
Description: Surgical procedure precisely injects DNX-2401 through a catheter (small tube) into brain tumor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNX-2401
Description: Surgical procedure precisely injects DNX-2401 through a catheter (small tube) into brain tumor.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Removal
Description: Surgical Tumor Resection
Study: NCT04041791

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzyl penicillin
Description: Benzyl penicillin is a penicillin antibiotic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzyl penicillin
Description: Benzyl penicillin is a penicillin antibiotic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin Sulfate
Description: Gentamicin is an aminoglycoside antibiotic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin Sulfate
Description: Gentamicin is an aminoglycoside antibiotic.
Study: NCT01704105

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Handwashing
Description: Hardware: Handwashing dual tippy tap stations, including jugs for clean and for soapy water. Handwashing stations will be stocked with soap for the duration of the trial.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on handwashing with soap at critical times around food preparation, defecation, and contact with feces.
Study: NCT02872688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GanedenBC30
Study: NCT04289272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dove Confident Me
Description: Dove Confident Me is a school-based intervention co-created by researchers at La Trobe University (Australia), the Centre for Appearance Research UWE, teachers, students, and education experts, and the Dove Self-Esteem Project (the social mission for personal care brand Dove). The five-session intervention is aimed at adolescents aged between 11-13 years, and targets recognised risk factors for body dissatisfaction, by addressing societal appearance ideals (Session 1), media literacy (Session 2), appearance comparisons (Session 3), appearance-related conversations and teasing (Session 4), and promoting 'body activism' (Session 5). The intervention consists of classroom-based discussion and small group activities, and uses audio-visual materials and worksheets to facilitate learning.
Study: NCT01681303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-120
Study: NCT01424163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose reduced
Description: Treatment 1 (Part A)
Study: NCT02303938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical exercise
Description: Patients in the intervention group will undergo a 6-month home-based exercise intervention. Patients will exercise (e.g., running, biking, swimming) three times per week for 6 months. Session duration will vary between 20 minutes and 45 minutes.
Study: NCT03696667

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BCI
Description: As participants listen to the music, the EEG waves of their affective states and their variations detected in real-time is converted into an auditory signal providing direct feedback to participants about their affective states and assisting participants to learn and practice emotion regulation.
Study: NCT01141543

Intervention type: DRUG
Intervention: Plerixafor (mozobil)
Description: Cohort 1: Administration of PLERIXAFOR (240mcg/kg sc) before the first dose of FLUDARABINE and BUSULFAN Cohort 2: Administration of PLERIXAFOR (240mcg/kg sc) before the first and second dose of FLUDARABINE and BUSULFAN.~Cohort 3: Administration of PLERIXAFOR (240mcg/kg sc) before the first, second, and third dose of FLUARABINE and BUSULFAN Cohort 4: Administration of PLERIXAFOR (240mcg/kg sc) before all four doses of FLUDARABINE and BUSULFAN

Intervention type: DRUG
Intervention: Plerixafor (mozobil)
Description: Cohort 1: Administration of PLERIXAFOR (240mcg/kg sc) before the first dose of FLUDARABINE and BUSULFAN Cohort 2: Administration of PLERIXAFOR (240mcg/kg sc) before the first and second dose of FLUDARABINE and BUSULFAN.~Cohort 3: Administration of PLERIXAFOR (240mcg/kg sc) before the first, second, and third dose of FLUARABINE and BUSULFAN Cohort 4: Administration of PLERIXAFOR (240mcg/kg sc) before all four doses of FLUDARABINE and BUSULFAN

Intervention type: DRUG
Intervention: Plerixafor (mozobil)
Description: Cohort 1: Administration of PLERIXAFOR (240mcg/kg sc) before the first dose of FLUDARABINE and BUSULFAN Cohort 2: Administration of PLERIXAFOR (240mcg/kg sc) before the first and second dose of FLUDARABINE and BUSULFAN.~Cohort 3: Administration of PLERIXAFOR (240mcg/kg sc) before the first, second, and third dose of FLUARABINE and BUSULFAN Cohort 4: Administration of PLERIXAFOR (240mcg/kg sc) before all four doses of FLUDARABINE and BUSULFAN

Intervention type: DRUG
Intervention: Plerixafor (mozobil)
Description: Cohort 1: Administration of PLERIXAFOR (240mcg/kg sc) before the first dose of FLUDARABINE and BUSULFAN Cohort 2: Administration of PLERIXAFOR (240mcg/kg sc) before the first and second dose of FLUDARABINE and BUSULFAN.~Cohort 3: Administration of PLERIXAFOR (240mcg/kg sc) before the first, second, and third dose of FLUARABINE and BUSULFAN Cohort 4: Administration of PLERIXAFOR (240mcg/kg sc) before all four doses of FLUDARABINE and BUSULFAN
Study: NCT03823885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-cigarette
Description: use e-cig for 30 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: empty (-cigarette sham control)
Description: use empty e-cig (sham control)
Study: NCT03002909

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: epidural catheter
Study: NCT01424163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose standard
Description: Treatment 2 (Part A)
Study: NCT03002909

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: preperitoneal catheter
Study: NCT01205737

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TL011
Description: 375 mg/m2 iv every 3 weeks for 8 cycles

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m2 iv every 3 weeks for 8 cycles
Study: NCT03152890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: If blood glucose level after reperfusion of liver graft exceeds 180 mg/dL, the insulin dose proposed by the linear mixed effects analysis is given as a bolus.
Study: NCT02681042

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure
Description: The SentreHeart Lariat® device (that is approved for soft tissue ligation) will be used to ligate or close the left atrial appendage as a stand-alone procedure at the participating centers.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SentreHeart Lariat®
Description: The SentreHeart Lariat® device (that is approved for soft tissue ligation) will be used to ligate or close the left atrial appendage as a stand-alone procedure at the participating centers.
Study: NCT04032431

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telerehab VR intervention
Description: Training with VR system using software specifically designed to reproduce activities of daily living

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehab VR intervention
Description: Training with VR system using software specifically designed to reproduce activities of daily living
Study: NCT04591132

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kinematic analysis
Description: motor tasks appropriate for each diagnosis will be recorder with wearable inertial sensors
Study: NCT01642849

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high protein diet
Description: 6 months on HP diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high carbohydrate diet
Description: 12 subjects will be placed on a hig carbohydrate diet for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high carbohydrate diet
Description: 12 subjects will be placed on a hig carbohydrate diet for 6 months
Study: NCT01424163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple Dose
Description: Treatment 3 (Part A)
Study: NCT04041791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Description: Ceftriaxone is a third generation cephalosporin antibiotic active against a wide range of gram negative and positive bacteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Description: Ceftriaxone is a third generation cephalosporin antibiotic active against a wide range of gram negative and positive bacteria.
Study: NCT04041791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin Clavulanate
Description: Amoxicillin Clavulanate is a combination of amoxicillin, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin Clavulanate
Description: Amoxicillin Clavulanate is a combination of amoxicillin, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous fluid
Description: Maintenance fluids administered for at least 24 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous fluid
Description: Maintenance fluids administered for at least 24 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous fluid
Description: Maintenance fluids administered for at least 24 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasogastric feeds
Description: Feeds given via nasogastric tube. Feeds may include cow's milk, breast milk, porridge, formula among others.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasogastric feeds
Description: Feeds given via nasogastric tube. Feeds may include cow's milk, breast milk, porridge, formula among others.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasogastric feeds
Description: Feeds given via nasogastric tube. Feeds may include cow's milk, breast milk, porridge, formula among others.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin
Description: Ampicillin is a penicillin-type antibiotic.
Study: NCT01704105

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Handwashing
Description: Hardware: Handwashing dual tippy tap stations, including jugs for clean and for soapy water. Handwashing stations will be stocked with soap for the duration of the trial.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on handwashing with soap at critical times around food preparation, defecation, and contact with feces.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition
Description: Supplement: Lipid-based Nutrient Supplement (LNS) twice daily from ages 6 to 24 months.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages modeled on those recommended in the Guiding Principles for Complementary Feeding of the Breastfed Child and the recent UNICEF Program Guide for Infant and Young Child Feeding Practices. General messages will include (1) practice exclusive breastfeeding from birth to 6 months of age and introduce complementary foods at 6 months of age while continuing to breastfeed; (2) continue breast feeding as you did before receiving LNS; (3) provide your child micronutrient-rich foods such as meat, fish, eggs, and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old.
Study: NCT04041791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ampicillin
Description: Ampicillin is a penicillin-type antibiotic.
Study: NCT00206076

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: mycophenolate mofetil and half their baseline dose of calcineurin inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: mycophenolate mofetil monotherapy
Study: NCT01704105

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition
Description: Supplement: Lipid-based Nutrient Supplement (LNS) twice daily from ages 6 to 24 months.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages modeled on those recommended in the Guiding Principles for Complementary Feeding of the Breastfed Child and the recent UNICEF Program Guide for Infant and Young Child Feeding Practices. General messages will include (1) practice exclusive breastfeeding from birth to 6 months of age and introduce complementary foods at 6 months of age while continuing to breastfeed; (2) continue breast feeding as you did before receiving LNS; (3) provide your child micronutrient-rich foods such as meat, fish, eggs, and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old.
Study: NCT03981731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac coherence
Description: An initiation session to cardiac coherence will take place between D-10 and D-7 before the operation (during the anaesthesia consultation) in order to obtain a breathing rate of 6 cycles/min via a free application (Respirelax) with listening to an audio tape.~3 cardiac coherence sessions per day of 5 min (before meals) during the 7 days preceding the operation.~- The anaesthetic induction will be done with a session of cardiac coherence associated with listening to the audio tape.
Study: NCT01832922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Study: NCT00735176

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical arthroplasty
Description: Anterior cervical discectomy, followed by insertion of the Discover™ Artificial Cervical Disc

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Description: Anterior cervical discectomy and decompression, followed by insertion of a PEEK cage, which induces fusion.
Study: NCT02620137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multicentrum® (Pfizer, Spain) 3 months
Description: The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multicentrum® (Pfizer, Spain) 12 months
Description: The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 12 months
Study: NCT03125408

Intervention type: DIAGNOSTIC_TEST
Intervention: HCV Assay
Description: Molecular diagnostic test to detect Hepatitus C
Study: NCT01103713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin plus chloroquine
Description: Study drug is a fixed dose tablet of AZCQ containing 250 mg AZ and 155 mg CQ base. All subjects will be administered a 3 day course of AZCQ IPTp regimen: a single dose of 1000 mg AZ/620 mg CQ base (4 fixed dose combination tablets of AZCQ: 250mg/155mg) administered per os (PO, orally) once daily for 3 days (Days 0, 1, 2).
Study: NCT03658954

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advice
Description: Once per week for two weeks, participants will come to in-person visits to receive brief web-based sleep health advice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advice
Description: Once per week for two weeks, participants will come to in-person visits to receive brief web-based sleep health advice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advice
Description: Once per week for two weeks, participants will come to in-person visits to receive brief web-based sleep health advice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Description: Participants will complete daily smartphone-based sleep and alcohol diaries for two weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Description: Participants will complete daily smartphone-based sleep and alcohol diaries for two weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Description: Participants will receive feedback once per week for two weeks on their sleep and alcohol consumption, using all possible data derived from Philips actiwatches and SCRAM ankle biosensors \& tailored coaching with a health coach
Study: NCT02933658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study: NCT01654419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Class II elastics and Sliding Jig
Description: Class II elastics, 3/16 6 oz, used daily for 3 months 24 hours per day and sliding jig orthodontic device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Class II elastic alone
Description: Elastics Class II alone, used 24 hours per day for 3 months from the hook of the upper canine to the first lower molar hook
Study: NCT01360138

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical epidural steroid injection
Description: cervical epidural steroid injection with a solution (5 ml) containing 10 mg triamcinolone acetonide suspension, 1.5 ml of 0.75% levobupivacaine hydrochloride, and 3.5 ml of normal saline (0.9% NaCl)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical epidural steroid injection
Description: cervical epidural steroid injection with a solution (5 ml) containing 10 mg triamcinolone acetonide suspension, 1.5 ml of 0.75% levobupivacaine hydrochloride, and 3.5 ml of normal saline (0.9% NaCl)
Study: NCT01731457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept
Description: adding appropriate dose of etanercept to the perfusion fluid
Study: NCT02144844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Insight-Plus Cognitive Behavioral Intervention
Description: Insight-Plus is a 6-session, manualized, cognitive behavioral intervention (CBI) culturally tailored for a diverse group of rural low-income women at low and high risk for antepartum depression.
Study: NCT03633760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine 40mg single dose
Description: Single-dose only cohort treatment duration is 1 day. After the screening period, eligible subjects will be allocated to receive a single dose of 40 mg of bilastine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine 20mg single-dose followed by multiple-dose
Description: Single-dose followed by multiple-dose cohort treatment duration of this cohort is 9 days. Subjects will receive a single dose of bilastine 20 mg on the morning of Day 1; and six doses of bilastine 20 mg in the morning from Day 4 to Day 9.